Cuprina Holdings (Cayman) Limited responds to unusual trading activity, reaffirming its operational status and mission-driven focus. The company emphasizes its compliance, pipeline advancement, and commitment to delivering value to patients and shareholders. CEO David Quek assures investors of the company’s healthy operational position and ongoing execution of its business plan. Cuprina highlights key milestones, including FDA clearance submission for medical maggot therapy and expansion into the Gulf Cooperation Council region. The company remains dedicated to transparency, integrity, and growth potential, with no founding team members selling stock recently. Investors are encouraged to stay informed through timely disclosures and filings.

Read more at GlobeNewswire: Cuprina Reaffirms Commitment to Shareholders and Patients